GW Pharmaceuticals plc and its US Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled …

LONDON and CARLSBAD, Calif., Sept. 27, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that EPIDIOLEX® (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S. Drug Enforcement Administration (DEA). EPIDIOLEX, which was approved by the U.S. Food and Drug Administration (FDA) on June 25, 2018 for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older, is the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs).

“We are pleased that the DEA has placed EPIDIOLEX in

... read more at: https://globenewswire.com/news-release/2018/09/27/1577277/0/en/GW-Pharmaceuticals-plc-and-its-U-S-Subsidiary-Greenwich-Biosciences-Announce-the-DEA-has-Rescheduled-EPIDIOLEX-cannabidiol-Oral-Solution-to-Schedule-V.html

by

Leave a Reply